
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Click here to register and receive these exclusive pdfs. After registering, you will be redirected to the page with the links to download.
Register with Psychiatric Times to receive these exclusive pdfs: "2010 Staff Salary Survey: Regional Data" and "What Should You Pay Staff?"
Sign up today and join our growing online community of healthcare professionals.
As a registered member you'll be able to:
Click




